Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Haukeland University Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00354081CT.gov WENBIT - Western Norway B Vitamin Intervention Trial | — | Completed | — | — | — |
NCT00004734CT.gov Vitamin Therapy for Prevention of Stroke | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myocardial Infarction
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vibisone (this asset) | Haukeland University Hospital | P3 | BB · 66 |
| Aspirin | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | A |
| Clopidogrel | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | A |
| Ticagrelor | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Folic Acid | Hamilton Health Sciences Corporation | P4 | BBB |
| Pyridoxol | Hamilton Health Sciences Corporation | P4 | BBB |
| Dabigatran | St. Antonius Hospital | P4 | BB |
| Atenolol | The George Institute | P4 | BB |
| Exenatide | Saint Luke's Health System | P4 | BB |
+29 more in the Myocardial Infarction cohort
Other indications for Vibisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glucose Intolerance | — | P4 | BB · 69 |
| Obesity Disorder | — | P4 | BB · 65 |
| Cerebral Infarction | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vibisone in Myocardial Infarction. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vibisone-myocardial-infarction
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →